Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus; ODM derived from:


Versions (1) ▾
  1. 7/9/19
Copyright Holder:
Uploaded on:

July 9, 2019

No DOI assigned. To request one please log in.
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Squamous Cell Carcinoma of Esophagus NCT02041819

Eligibility Squamous Cell Carcinoma of Esophagus NCT02041819

Inclusion Criteria
histologically confirmed squamous cell carcinoma of the thoracic esophagus, including the gastroesophageal junction (siewert type i)
locally advanced disease that is technically operable with curative intent (r0)
t3, n0 or t1-3, n+ or t4, nx
no t1-2, n0
no inoperable t4 (unequivocal organ involvement)
no distant metastasis, including m1a lymph node status
lymph nodes suspicious of m1a status by ct scan, pet scan, or ultrasound must be verified by fine-needle aspiration cytology
no carcinoma of the cervical esophagus
obstructive tumors allowed
Exclusion Criteria
not suitable to surgery
cervical esophageal carcinoma(distance of incisor tooth<19cm)
early esophageal carcinoma(stage i)
complete esophageal obstruction,esophageal perforation or hematemesis
other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ
pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives
uncontrolled seizures or psychiatric diseases, loss of control over their own behavior
history of serious allergic or castor oil allergy
patients who are not suitable to participate in the trial according to researchers